Clanotech was founded in 2006 by Prof. Yihai Cao, Karolinska Institutet.

CLT-28643 is NCE lead candidate emerged from a Medicinal Chemistry effort by chemical expansion of novel templates identified from the in vitro screening of "small-molecule" compounds-libraries. This lead compounds demonstrated good drug properties along with in vivo efficacy in an extensive variety of pre- clinical models relevant for studing the anti-agiogenic and anti-fibrotic effects: xenografts and synografts, models of retinal angiogenesis (CNV, ROP, Zebra fish), models of fibrosis (belomycin induced lung fibrosis and scarring after glaucoma surgery).